Michal Bar-Natan

Michal Bar-Natan, MD, is Associate Professor (Pending Appointment at Rank) of Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City.
Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.
Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute.
Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.

Gail J.Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA.

Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital.

Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

Michal Bar-Natan, MD, is Associate Professor (Pending Appointment at Rank) of Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City.
Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.
Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute.
Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.

Dr. Alexandra Gomez-Arteaga is an Assistant Professor at Weill Cornell Medicine/NewYork-Presbyterian Hospital and directs the Allogeneic Bone Marrow Transplant Service and the Advanced Fellowship in Bone Marrow Transplantation. She earned her MD from Los Andes University, completed her residency at the University of Miami, her Hematology/Oncology fellowship at Weill Cornell, and her BMT advanced fellowship at Memorial Sloan Kettering Cancer Center. Dr. Gomez’s research focuses on improving outcomes in allogeneic stem cell transplantation for leukemia and myeloid malignancies, with an emphasis on young adults and alternative donors. Her work also addresses the critical need to decrease disparities in access to transplantation for minority populations, a cause she champions across her clinical practice, research, and advocacy. She currently serves as the Co-Chair for the Junior Faculty Initiative within the ASTCT ACCESS Initiative.

Dr. Elias Jabbour is Professor of Medicine and Chief of the Acute Lymphoblastic Leukemia (ALL) Section in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. A world-renowned physician-scientist, he has authored more than 1,000 peer-reviewed publications and is recognized internationally for pioneering advances in the treatment of acute and chronic leukemias.

Over his career, Dr. Jabbour has led pivotal clinical trials that resulted in the approval of multiple therapies for CML, MDS, and ALL, transforming standards of care and improving patient survival worldwide. His groundbreaking work includes defining resistance mechanisms to TKIs, establishing novel frontline regimens for CML, and developing innovative targeted and combination therapies for ALL, including strategies that have significantly advanced outcomes for patients with Philadelphia chromosome–positive ALL.

Through his leadership and vision, Dr. Jabbour continues to shape the field of hematologic oncology, driving forward the integration of precision medicine and next-generation therapeutics to improve outcomes for patients across the globe.

Dr. Marlise Luskin received her MD from the University of Pennsylvania Perelman School of Medicine in 2009. She completed residency and chief residency in Internal Medicine at Brigham and Women’s Hospital in 2012, followed by fellowship training in Hematology and Oncology at the University of Pennsylvania in 2015. In 2016, she joined the Division of Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts, where she cares for patients with leukemia. Dr. Luskin's clinical and research interests include acute lymphoblastic leukemia, acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, chronic myeloid leukemia, and the care of young adults with leukemia. Dr. Luskin is also Associate Program Director of the Dana-Farber/MGB Hematology/Oncology Fellowship, Director of the Foley Family Fellowship in Leukemia, and Education Director for the Division of Leukemia.